Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4).

被引：0
|
作者：
Li, Jianyong
Tao, Rong
Fan, Lei
Song, Yongping
Hu, Yu
Zhang, Wei
Wang, Yafei
Xu, Linxinyu
Sun, Xing
Zhou, Hui
机构：
[1] Jiangsu Prov Hosp, Nanjing, Peoples R China
[2] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[6] Peking Union Med Coll Hosp, Beijing, Peoples R China
[7] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[8] Innovent Biol Inc, Suzhou, Peoples R China
[9] Innovent Biol Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8050
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
    Sehn, Laurie H.
    Hertzberg, Mark
    Opat, Stephen
    Herrera, Alex F.
    Assouline, Sarit
    Flowers, Christopher R.
    Kim, Tae Min
    McMillan, Andrew K.
    Ozcan, Muhit
    Safar, Violaine
    Salles, Gilles
    Hirata, Jamie
    Yang, Annie
    Musick, Lisa
    Matasar, Matthew J.
    BLOOD, 2022, 140 : 9464 - 9467
  • [42] L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)-A single-arm phase II study.
    Maddocks, Kami J.
    Barca, Eva Gonzalez
    Jurczak, Wojciech
    Liberati, Anna Marina
    Duell, Johannes
    Nagy, Zsolt
    Papajik, Tomas
    Andre, Marc
    Kalakonda, Nagesh
    Dreyling, Martin H.
    Zinzani, Pier Luigi
    Ambarkhane, Sumeet Vijay
    Weirather, Johannes
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis
    Siegel, D. S. D.
    Martin, T.
    Wang, M.
    Vij, R.
    Lonial, S.
    Kukreti, V.
    Bahlis, N. J.
    Alsina, M.
    Somlo, G.
    Buadi, F.
    Reu, F. J.
    Song, K. W.
    Kunkel, L. A.
    Wong, A.
    Vallone, M.
    Orlowski, R. Z.
    Stewart, A. K.
    Singhal, S.
    Jagannath, S.
    Jakubowiak, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] CheckMate 436: Extended Follow-Up from the Phase 2 Study Investigating Nivolumab Plus Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL)
    Zinzani, Pier Luigi
    Santoro, Armando
    Gritti, Giuseppe
    Brice, Pauline
    Barr, Paul
    Cunningham, David
    Kline, Justin
    Johnson, Nathalie
    Mehta-Shah, Neha
    Fanale, Michelle
    Francis, Stephen
    Moskowitz, Alison
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S398 - S399
  • [45] A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma
    Huangming Hong
    Zegeng Chen
    Mingzhi Zhang
    Zhigang Peng
    Jianzhen Shen
    Yuerong Shuang
    Hui Zhou
    Hongqiang Guo
    He Huang
    Fei Li
    Zhengzi Qian
    Lihong Liu
    Liang Wang
    Wei Yang
    Liling Zhang
    Pengcheng He
    Shen Qian
    Fugen Li
    Meng Li
    Tongyu Lin
    Journal of Hematology & Oncology, 18 (1)
  • [46] A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
    Hong, Huangming
    Zhang, Mingzhi
    Peng, Zhigang
    Shen, Jianzhen
    Shuang, Yuerong
    Zhou, Hui
    Guo, Hongqiang
    Huang, He
    Li, Fei
    Qian, Zhengzi
    Liu, Lihong
    Wang, Liang
    Yang, Wei
    Zhang, Liling
    He, Pengcheng
    Qian, Shen
    Li, Fugen
    Li, Meng
    Lin, Tongyu
    BLOOD, 2023, 142
  • [47] Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
    Huang, Huiqiang
    Zhu, Jun
    Yao, Ming
    Kim, Tae Min
    Yoon, Dok Hyun
    Cho, Seok-Goo
    Eom, Hyeon Seok
    Lim, Soon Thye
    Yeh, Su-peng
    Song, Yuqin
    Kwong, Yok Lam
    Kim, Jin Seok
    Jin, Jie
    Shi, Yuankai
    Kim, HyeJin
    Qing, Min
    Zhou, Tianyuan
    Gao, Grace
    Dong, Zongqi
    Qi, Ming
    Kim, Won Seog
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [48] Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
    Huiqiang Huang
    Jun Zhu
    Ming Yao
    Tae Min Kim
    Dok Hyun Yoon
    Seok-Goo Cho
    Hyeon Seok Eom
    Soon Thye Lim
    Su-peng Yeh
    Yuqin Song
    Yok Lam Kwong
    Jin Seok Kim
    Jie Jin
    Yuankai Shi
    HyeJin Kim
    Min Qing
    Tianyuan Zhou
    Grace Gao
    Zongqi Dong
    Ming Qi
    Won Seog Kim
    Journal of Hematology & Oncology, 14
  • [49] Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial
    Shi, Y-K.
    Cui, J.
    Zhou, H.
    Zhang, X.
    Zou, L. Q.
    Liu, H.
    Zhang, H.
    Li, X.
    Zhang, W.
    Zhou, F.
    Zhong, L.
    Jin, C.
    Zhang, H.
    Peng, Z.
    Gao, Y.
    Cao, J.
    Ma, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S775 - S776
  • [50] A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
    Konopleva, Marina Y.
    Bhatt, Vijaya Raj
    Mantzaris, Ioannis
    Maiti, Abhishek
    Gundabolu, Krishna
    Jensen, Kyle
    Schafer, Jolie
    Mi, Gu
    Drewniak, Agata
    Krenz, Heidi
    Saleem, Rao
    Abbadessa, Giovanni
    Daver, Naval
    BLOOD, 2023, 142
12345